NEW FDA APPROVED TREATMENT FOR MIGRAINES - Manhattan Center for Headache & Neurology

NEW FDA APPROVED TREATMENT FOR MIGRAINES

NEW FDA APPROVED TREATMENT FOR MIGRAINES

The U.S. Food and Drug Administration just approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

May 26, 2025 Uncategorized

×

The Manhattan Center for Headache and Neurology is Permanently Closed

We are grateful to have been a part of your healthcare journey.

We will provide updated information about our providers and their future plans here as it becomes available.

If you have questions or would like to request your medical records, please email us at ahalpernmd.temp@gmail.com.

Further updates will be posted on this website.